On May 13, ImmunityBio faced a securities class action lawsuit after the FDA issued a warning regarding misleading efficacy claims for its product Anktiva. The news caused IBRX shares to plunge by 21%, resulting in an approximate loss of $2 billion in market capitalization.
HUBG stock plummeted after the company invalidated its 2023-2024 financial statements and announced it would miss the filing deadline for its Q1 2026 report.
Read the full storySportradar Group AG shares plummeted following critical reports from Muddy Waters and Callisto Research alleging the company misled investors regarding its business legality.
SMCI faces a new class action lawsuit alleging the concealment of illegal AI server sales involving restricted Nvidia chips, sparking regulatory concerns among investors.
The global beauty firm faces investor litigation following the withdrawal of its 2026 guidance and operational issues that triggered a stock decline.
ImmunityBio faces a class action lawsuit after an FDA warning over misleading efficacy claims for its cancer drug Anktiva triggered a $2 billion market value wipeout.